Unity Biotechnology, Inc. (UBX) Dividend History

Unity Biotechnology, Inc. (UBX) focuses on developing therapeutics aimed at slowing, halting, or reversing age-related diseases by targeting senescent cells, which are associated with aging and age-related conditions. The company's research centers on leveraging senolytic drug candidates to improve health span and treat conditions such as osteoarthritis, age-related eye diseases, and other degenerative disorders.

285 East Grand Avenue, South San Francisco, CA, 94080
Phone: (650) 416-1192
Website:

Dividend History

Unity Biotechnology, Inc. currently does not pay dividends

Company News

  • All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy

    UNITY Biotechnology (UBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    Zacks Investment Research
  • Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. (NASDAQ: UBX) from $10 to $8. HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating. Unity Biotechnology shares gained 1.3% to close at $1.52 on Tuesday. See how other analysts view this stock. TD Cowen slashed the price target for Amgen Inc. (NASDAQ: AMGN) from $370 to $360. TD Cowen analyst Yaron Weber maintained the stock with a Buy rating. Amgen shares rose 0.1% to close at $265.64 on Tuesday. See how other analysts view this stock. B of A Securities cut Johnson & Johnson (NYSE: JNJ) price target from $180 to $170. B of A Securities analyst Geoff Meacham maintained a Neutral rating. Johnson & Johnson shares fell 2.1% to close at $144.45 on Tuesday. See how other analysts view this stock. Morgan Stanley raised the price target ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: AMGN AR BK JBHT JNJ STRA URBN V
  • UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

    UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates.

    GlobeNewswire Inc.
  • Unity Biotechnology Upgraded - Analyst Highlights Cash Strength & Execution

    Wedbush analyst Andreas Argyrides upgraded the shares of Unity Biotechnology Inc (NASDAQ: UBX) from Neutral to Outperform and raised the price target from $2 to $4. Unity Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. Unity's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases. Following the positive 12 week, 18 week, 24 week and 48 week results from the Ph2 BEHOLD trial for UBX1325/DME, the company is set to initiate a head-to-head Ph2b trial for UBX1325 against aflibercept in patients with DME later ...Full story available on Benzinga.com

    Benzinga
  • UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 04:12:19 UTC